C26.F CellaVision AB (publ)

Healthcare Health Care Equipment & Supplies Frankfurt Exchange
18.80 EUR
Close of Nov 12, 2026
10.64 18.22
Market cap
EUR 448M
P/E
34.1x
P/B
5.11x
ROE
13.6%
Dividend yield
1.40%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is C26.F undervalued?

Graham number
Price18.80
Graham value6.75
Premium178.4%

C26.F trades 178.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CellaVision AB (publ) fundamental analysis

No fundamental analysis for CellaVision AB (publ) yet.

CellaVision AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CellaVision AB (publ)

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 fo…

Full company profile